Ignite Creation Date:
2024-05-06 @ 1:40 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04080869
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2019-09-04
Brief Title:
Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris a Split-face Comparative Clinical Study
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acne is a chronic inflammatory dermatosis of the pilosebaceous unit Topical treatment is the first choice in mild and moderate cases of acne especially topical retinoids Although topical retinoids are very effective in the treatment of acne local cutaneous irritation including burning itching erythema peeling or dryness is observed in a considerable number of patients resulting in low patient compliance compromising the efficacy of the therapy
Several approaches have been proposed to address these concerns including the use of esters of retinoic acid RA and RA precursors such as retinol and retinaldehyde or novel drug delivery systems which present the potential for controlled release in turn reducing the aforementioned occurrences
Encapsulation of retinoids into vesicular carriers as liposomes and ethosomes and nanoparticulate carriers can significantly improve their effects for the treatment of acne compared with commercial formulations providing better tolerability of irritating retinoid
The aim of work is to assess the efficacy and tolerability of the topical application of Retinyl Palmitate-loaded ethosome formulation in the treatment of acne vulgaris in comparison to conventional formulation of classic retinoids
Several approaches have been proposed to address these concerns including the use of esters of retinoic acid RA and RA precursors such as retinol and retinaldehyde or novel drug delivery systems which present the potential for controlled release in turn reducing the aforementioned occurrences
Encapsulation of retinoids into vesicular carriers as liposomes and ethosomes and nanoparticulate carriers can significantly improve their effects for the treatment of acne compared with commercial formulations providing better tolerability of irritating retinoid
The aim of work is to assess the efficacy and tolerability of the topical application of Retinyl Palmitate-loaded ethosome formulation in the treatment of acne vulgaris in comparison to conventional formulation of classic retinoids
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None